Ensign Group shares closed at $170.30 on June 5. On June 8 they closed at $156.42. The drop was $13.88, or about 8.15%, in one session. The bottom line for investors: a short-seller’s report knocked a nursing home operator’s stock sharply lower, and the lawyers have been circling ever since.
The trigger was a June 8 report from Hunterbrook Media, the investigative arm of a firm that says it is short Ensign stock. That disclosure matters. Hunterbrook stands to profit if the price falls, so its claims are allegations, not findings by a court or a regulator.
What the report claims
Hunterbrook describes a five-month investigation and says Ensign’s profits depend heavily on understaffing its facilities. It argues that Ensign scores better than average on quality measures it reports about itself, and worse on measures that outsiders can verify. The report also says Ensign moves taxpayer money to its executives and to affiliated companies.
Then come the numbers. Hunterbrook says nursing hours at Ensign facilities between July and November 2024 fell short of what residents needed by 5 million hours. Closing that gap, it estimates, would have cost about $161 million over the period, or roughly $386 million a year. Ensign’s reported net income that year was $298 million. The report also says Ensign paid more than $339 million to its own affiliates in 2024, about 8% of revenue.
Ensign did not answer Hunterbrook’s detailed requests for comment. CEO Barry Port had told The Arizona Republic in 2023 that individual facility management decides staffing, and that the suggestion his company siphons money to boost profit is “categorically false.” Ensign runs 334 nursing facilities in 17 states, according to the report.
A second report, then the law firms
Three days later Muddy Waters Research published its own report. It alleged that Ensign used administrators’ licenses at some facilities in ways that could raise Medicare, Medicaid and compliance problems. The stock fell another $4.52, or about 2.98%, to $147.13 on June 11 from $151.65 the day before.
Law firms moved quickly. Bleichmar Fonti & Auld, known as BFA, said it was investigating whether Ensign broke federal securities law, with a focus on statements about care quality, growth and margins, and regulatory compliance. Pomerantz, Kaplan Fox & Kilsheimer, Hagens Berman Sobol Shapiro and Bronstein, Gewirtz & Grossman announced probes too. Investor-rights firms routinely do this after a big price fall, and an investigation proves nothing by itself.
Where it stood by autumn
The cases have since grown. A shareholder filed a derivative complaint on July 16 in Orange County Superior Court in California, captioned Thompson v. Keetch. Later, Bloomberg Law reported that investor Nicholas Perusek filed a proposed class action covering buyers of Ensign stock between Feb. 10, 2022, and June 18, 2026. It names Ensign, Port and CFO Suzanne D. Snapper, and accuses them of misleading statements in annual reports and earnings releases.
The market has been less shaken than the lawyers. Ensign closed at $175.18 on September 25, above its pre-report price, and it reported second-quarter results in July as usual.
Sources
- Ensign Group Faces Growing Investor Investigations (STL.News)
- Nursing Home Operator Accused of Concealing Patient Care Issues (Bloomberg Law)
- Ensign: The Nursing Home Empire Built on Fatal Neglect (Hunterbrook Media)
